GLP-1 Cost and Access: The 2026 Insurance and Pricing Guide

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Wegovy's list price is about $1,350 per month for both the weekly injection and daily pill.
Without insurance, cash prices for Wegovy can range from $149-$349 per month, depending on the form.
Insurance coverage for GLP-1s like Wegovy varies; expect to pay $25–$150 monthly with a plan.
New uninsured and self-pay Ozempic patients can pay $25 per month for the first 2 months of 0.25 mg or 0.5 mg doses.

GLP-1 medications like Wegovy and Ozempic are effective for managing weight and diabetes, but understanding their cost in 2026 can be complex. While the list price for Wegovy remains around $1,350 per month for both the weekly injection and the new daily pill, what patients actually pay can vary widely [https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV]. Insurance coverage plays a big role, with estimated monthly costs ranging from $25 to $150 for insured patients. For those without insurance, cash-pay prices for the Wegovy injection pen are typically $199–$349 per month, and the Wegovy pill costs $149–$299 per month through specific pharmacy programs. Manufacturer savings programs, like those offered for Ozempic, can further reduce these out-of-pocket expenses. Staying informed about these shifting prices, government regulations, and available assistance is key to making informed decisions about GLP-1 treatment.

What is the List Price for GLP-1 Medications?

The list price for GLP-1 medications, specifically Wegovy, remains a consistent benchmark for understanding the medication's overall cost. Wegovy carries a list price of about $1,350 per month, whether it is prescribed as the weekly injection pen or the new daily pill formulation [https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV]. This list price represents the manufacturer's suggested cost before any insurance coverage, discounts, or other savings programs are applied. It is the baseline figure from which all other pricing structures are derived, providing a starting point for patients and healthcare providers to assess the financial commitment involved.

Understanding the Retail Price

The retail price of Wegovy is $1349, which aligns closely with its stated list price [https://www.medicalnewstoday.com/articles/drugs-wegovy-cost]. This retail price is what a pharmacy might charge for the medication before any discounts or insurance adjustments. It serves as a transparent figure for consumers to understand the foundational cost of the drug. However, it's important to recognize that very few patients, if any, will actually pay this exact amount out-of-pocket without some form of financial assistance or insurance benefit. The retail price is a necessary disclosure, offering a clear view of the drug's value in the market before individual circumstances are considered.

Potential Savings on Retail Price

Even at the retail level, there are opportunities to reduce the cost. Patients may be able to save up to $55 per fill off of the retail price of Wegovy [https://www.medicalnewstoday.com/articles/drugs-wegovy-cost]. These savings often come through specific programs offered by the manufacturer or through prescription discount websites. While these discounts might seem modest compared to the overall price, they can provide some relief for patients, especially when combined with other forms of assistance. It is always recommended to explore all available savings options to minimize the financial burden.

Factors Affecting Your Final Cost

The final price you pay for Wegovy can be influenced by several factors beyond the list price. Your specific treatment plan, including the dosage and duration of therapy, will play a role. The type and extent of your insurance coverage are critical, as they determine how much your plan will contribute versus your out-of-pocket share. The choice of pharmacy can also affect the price, as different pharmacies may have varying agreements or pricing structures. Lastly, whether you qualify for the Wegovy savings program is a significant factor in reducing your out-of-pocket expenses [https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html]. These various elements interact to determine the true cost for each individual patient.

The Role of Manufacturer Programs

Manufacturer programs are designed to bridge the gap between the high list price and what patients can realistically afford. These programs often come in the form of savings cards, coupons, or patient assistance programs. They are crucial for improving access to medications like Wegovy, especially for those who are uninsured or have limited insurance coverage for weight-loss drugs. By participating in these programs, patients can significantly reduce their monthly costs, making long-term treatment more feasible. It is always advisable to check the manufacturer's website or speak with your healthcare provider about available assistance options.

Comparing List Price to Actual Cost

The substantial difference between the list price and what many patients ultimately pay highlights the complex nature of drug pricing in the healthcare system. While the $1,350 list price for Wegovy might seem daunting, it rarely reflects the actual out-of-pocket cost for a patient. Understanding this distinction is essential for anyone considering GLP-1 medications. Focusing solely on the list price can be misleading and might deter patients from exploring treatment options that could be more affordable through insurance, manufacturer programs, or cash-pay discounts.

How Much Does Wegovy Cost Without Insurance in 2026?

The cost of Wegovy without insurance in 2026 shows a significant shift from its high list price, with cash-pay options making the medication more accessible than before. Without insurance, cash-pay prices in 2026 typically range from about $199–$349 per month for the Wegovy injection pen [https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV]. This represents a substantial reduction from the $1,350 list price, reflecting the impact of various market dynamics and manufacturer initiatives.

Shifting Cash-Pay Landscape

The landscape for cash-pay prices has evolved due to several factors. Government rule and regulation changes have influenced how drugs are priced and distributed, creating more options for direct purchase. Manufacturer programs, such as those from Novo Nordisk, have played a significant role in offering more competitive prices to uninsured individuals. Additionally, how pharmacies handle cash-pay prescriptions has become more flexible, contributing to the wider range of prices observed. These combined forces have worked to bring down the effective cost for patients paying entirely out of pocket.

The New Wegovy Pill and Its Pricing

A major development for 2026 is the approval of the new Wegovy pill in late 2025. This oral formulation offers an alternative to the weekly injection, and its pricing is also competitive for cash-pay patients. Without insurance, the Wegovy pill typically costs $149–$299 per month through Novo Nordisk’s NovoCare Pharmacy [https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV]. This pricing makes the pill generally more affordable than the injection pen for those paying cash, offering a new choice based on cost and preference for administration. The introduction of the pill also adds another dimension to pricing considerations, as patients can now compare the daily pill versus the weekly injection in terms of both convenience and cost.

Novo Nordisk’s NovoCare Pharmacy

Novo Nordisk’s NovoCare Pharmacy is a key player in providing these reduced cash-pay prices. This direct-to-consumer channel allows the manufacturer to offer specific pricing that might not be available through all traditional retail pharmacies. For uninsured individuals or those whose plans do not cover weight-loss medications, utilizing manufacturer-specific pharmacies or programs can be a strategic way to access Wegovy at a more manageable cost. Patients should investigate if their prescription can be filled through such programs to take advantage of these lower rates.

Comparing Injection vs. Pill for Cash-Pay

When considering Wegovy without insurance, patients now have a clear choice between the injection pen and the pill, each with its own cash-pay price range. The injection pen, costing $199–$349 per month, offers the convenience of a weekly dose. The pill, at $149–$299 per month, provides a daily oral option that is often more budget-friendly for cash payers. This difference in price allows patients to weigh their preferences for administration against their budget constraints. The decision will often come down to what fits best into their lifestyle and financial situation, making it important to understand both options thoroughly. For more details, see Wegovy Cost & Coverage Information.

Navigating Out-of-Pocket Options

For those who are uninsured, whose insurance plans do not cover weight-loss medications, or who simply wish to understand their true out-of-pocket options, navigating the updated cost landscape requires diligence. It is essential to research current pricing, inquire about manufacturer programs, and compare options from different pharmacies. While GLP-1 medications like Wegovy can be very effective for managing weight, their cost without insurance is a significant factor in whether treatment will work for an individual. Staying informed about these shifting dynamics is crucial for making a well-informed decision about starting and continuing Wegovy treatment.

What Are the Costs with Insurance Coverage?

Insurance coverage significantly impacts the cost of GLP-1 medications like Wegovy, often reducing the financial burden for patients. With insurance, estimated monthly prices for Wegovy, covering both the injection and pill forms, typically fall within a range of $25–$150 [https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV]. This range reflects the variability in insurance plans, deductibles, and specific coverage terms for weight-loss medications. While the list price is high, insurance can make the drug much more affordable for many.

Variability in Insurance Plans

The exact amount you pay for Wegovy with insurance depends heavily on your specific plan and its benefits. Not all insurance plans cover weight-loss medications, or they may have strict criteria for coverage. Some plans might categorize Wegovy as a specialty drug, leading to higher co-pays or requiring prior authorization. Other plans might cover it with a standard co-pay, similar to other prescription drugs. It is crucial for patients to contact their insurance provider directly to understand their specific coverage details for GLP-1 medications. This step ensures there are no unexpected costs.

Changing Landscape of Weight-Loss Coverage

Historically, insurance rarely accepted coverage for medications used solely for weight loss. However, this trend is slowly changing. More insurance providers are starting to recognize the medical necessity of treating obesity, leading to increased, though still varied, coverage for GLP-1s like Wegovy. Despite this shift, patients should still expect to pay some amount out of pocket, as full coverage without any co-pay or deductible is uncommon. The evolving nature of insurance policies means that what was true last year might not be true in 2026, making it important to verify current benefits.

The Role of Co-pays and Deductibles

When insurance covers Wegovy, your out-of-pocket cost will likely include co-pays, deductibles, or co-insurance. A co-pay is a fixed amount you pay for each prescription fill. A deductible is an amount you must pay out of pocket before your insurance starts to cover costs. Co-insurance means you pay a percentage of the drug's cost after your deductible is met. These elements vary significantly between plans and can impact whether your monthly cost falls at the lower end ($25) or higher end ($150) of the estimated range. Understanding these terms is vital for budgeting your healthcare expenses.

Utilizing Drug Coupons with Insurance

For some patients, drug coupons and discount websites can offer prices that are lower than what they would pay through their insurance co-pay. While these coupons generally cannot be used with insurance benefits simultaneously, they can provide an alternative path to affordability. For example, if your insurance co-pay for Wegovy is $100, but a coupon offers the medication for $75, you might choose to use the coupon instead. It is always worth investigating these options and comparing them against your insurance-covered cost to find the most economical solution. This flexibility provides an important avenue for cost reduction.

Seeking Clarification from Your Provider

To find out what the cost of Wegovy will be for you, it is essential to talk with your doctor, pharmacist, or insurance provider [https://www.medicalnewstoday.com/articles/drugs-wegovy-cost]. Your doctor can provide insights into your treatment plan and potential costs. Your pharmacist can offer details on specific pharmacy prices and coupon availability. Your insurance provider is the definitive source for understanding your plan's coverage, deductibles, and any prior authorization requirements. Gathering information from all these sources will give you the clearest picture of your expected out-of-pocket expenses.

How Can Manufacturer Savings Programs Help?

Manufacturer savings programs are a crucial resource for patients seeking to reduce the high cost of GLP-1 medications. Novo Nordisk, the company behind both Wegovy and Ozempic, actively offers various programs designed to make these important drugs more affordable. These initiatives can significantly lower out-of-pocket expenses, making long-term treatment more manageable for many individuals. By providing direct financial assistance, manufacturers aim to improve patient access and adherence to prescribed therapies, recognizing the financial barriers that often exist.

Ozempic Savings Card for Commercially Covered Patients

For patients who have commercial insurance coverage for Ozempic, a specific savings card program is available. This program allows eligible individuals to pay as little as $25 for any dose of Ozempic for up to a 3-month prescription [https://www.ozempic.com/savings-and-resources/save-on-ozempic.html]. This is a substantial saving, effectively reducing the monthly cost to less than $10 for many patients. The Ozempic Savings Card helps to bridge the gap between what insurance covers and the remaining patient responsibility, making the medication significantly more accessible for those with commercial plans. It's a key tool for managing the ongoing costs associated with type 2 diabetes treatment.

Limited-Time Offers for Uninsured and Self-Pay Ozempic Patients

Recognizing the challenges faced by those without insurance or who are self-paying, Novo Nordisk also provides limited-time offers for Ozempic. New uninsured and self-pay patients can pay $25 per month for the first 2 months of Ozempic 0.25 mg or 0.5 mg doses [https://www.ozempic.com/savings-and-resources/save-on-ozempic.html]. This initial discount is particularly helpful for patients starting treatment, as it allows them to get established on the medication at a significantly reduced cost during the titration phase. While this offer is for a limited duration, it provides a crucial financial break at the beginning of therapy.

Savings for Existing Ozempic Patients

Existing uninsured and self-pay patients also have access to savings programs for Ozempic, though the specific terms may vary. These programs typically apply to Ozempic 0.25 mg, 0.5 mg, or 1 mg doses, and sometimes even the 2 mg dose [https://www.ozempic.com/savings-and-resources/save-on-ozempic.html]. While the exact monthly payment for existing patients is not specified as a fixed amount like the new patient offer, the existence of these programs indicates ongoing support for those who continue to pay out-of-pocket. Patients should regularly check the Ozempic website or speak with their pharmacist to understand the latest offers and their eligibility. For more details, see Wegovy Cost Without Insurance in 2026.

Wegovy Savings Programs

Wegovy also has a dedicated savings program that patients can investigate [https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html]. Similar to Ozempic, these programs are designed to help reduce the financial burden for eligible patients. Details about the Wegovy savings program, including eligibility requirements and specific benefits, can typically be found on the official Wegovy website. These programs are vital for patients prescribed Wegovy for weight management, especially given that insurance coverage for weight-loss medications can still be inconsistent. Exploring these options is a critical step in managing the overall cost of treatment.

How to Access Manufacturer Programs

Accessing these manufacturer savings programs usually involves visiting the official product website (e.g., Wegovy.com or Ozempic.com), checking eligibility criteria, and often downloading a savings card or coupon. Patients may need a valid prescription and to meet certain income or insurance status requirements. It's important to read all terms and conditions carefully. Working with your healthcare provider and pharmacist can also help streamline the process, as they may have direct knowledge of these programs and can assist with enrollment. These programs represent a significant opportunity to mitigate the financial impact of GLP-1 therapies.

The Impact of Subscription Plans

In a notable development for 2026, the maker of Wegovy has launched lower-cost subscription plans [https://www.powershealth.org/about-us/newsroom/health-library/2026/04/02/wegovy-maker-lunches-lower-cost-subscription-plans]. This innovative approach offers another avenue for patients to manage their medication costs. Subscription models can provide predictable monthly pricing, potentially reducing the variability and complexity often associated with traditional insurance and cash-pay systems. These plans could be particularly beneficial for patients seeking long-term treatment, offering a more stable financial outlook. Details on eligibility and pricing for these subscription plans would be available through the manufacturer or specific healthcare providers offering these services.

What Are the Key Safety Considerations for Wegovy®?

When considering Wegovy, understanding its safety profile is just as important as knowing its cost and how to access it. Wegovy can cause serious side effects, and patients must be aware of these potential risks before starting treatment. It is crucial to have an open discussion with your healthcare provider about your full medical history and any concerns you may have [https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html]. Being informed about the possible adverse events allows for early detection and management, ensuring the safest possible treatment journey.

Possible Thyroid Tumors, Including Cancer

One of the most important pieces of safety information about Wegovy concerns the risk of possible thyroid tumors, including cancer. Patients should tell their healthcare provider if they notice a lump or swelling in their neck, experience hoarseness, have trouble swallowing, or feel short of breath. These symptoms could indicate thyroid cancer. Studies in rodents showed that Wegovy and similar medications caused thyroid tumors, including thyroid cancer. However, it is not yet known if Wegovy will cause thyroid tumors or medullary thyroid carcinoma (MTC) in humans [https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html]. This uncertainty means vigilance is necessary.

Contraindications: When Not to Use Wegovy

There are specific conditions under which Wegovy should not be used. You should not use Wegovy if you or any of your family members have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Similarly, if you have an endocrine system condition known as Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), Wegovy is contraindicated. Additionally, do not use Wegovy if you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy injection or tablets. Recognizing these contraindications is vital for preventing severe adverse reactions [https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html].

Important Medical Conditions to Discuss

Before starting Wegovy, a comprehensive review of your medical history with your healthcare provider is essential. You must inform them if you have or have had problems with your pancreas or kidneys, as Wegovy can affect these organs. Patients with type 2 diabetes and a history of diabetic retinopathy should also disclose this, as it may influence treatment decisions. If you are scheduled for surgery or other procedures requiring anesthesia or deep sedation, your provider needs to know, as Wegovy slows stomach emptying, which can be a concern with certain medical procedures [https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html].

Pregnancy and Breastfeeding

Wegovy may harm an unborn baby. If you are pregnant or planning to become pregnant, you should discuss this with your doctor. It is recommended to stop using Wegovy 2 months before you plan to become pregnant. For breastfeeding mothers, or those planning to breastfeed, it is generally not recommended during treatment with Wegovy tablets. It is not known if Wegovy, when received through an injection, passes into breast milk. These considerations highlight the importance of family planning discussions with your healthcare team before and during Wegovy treatment [https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html].

Drug Interactions with Other Medications

It is crucial to tell your healthcare provider about all medicines you take, including prescription and over-the-counter drugs, vitamins, and herbal supplements. Wegovy can affect how some medicines work, and some medicines can affect how Wegovy works. Specifically, if you are taking other medicines for diabetes, such as sulfonylureas or insulin, your provider needs to be aware, as dose adjustments may be necessary. Because Wegovy slows stomach emptying, it can also impact medicines that need to pass through the stomach quickly, potentially affecting their absorption and effectiveness [https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html].

Serious Side Effects: Pancreatitis and Gallbladder Problems

Beyond thyroid concerns, Wegovy can cause other serious side effects. One such risk is inflammation of the pancreas, known as pancreatitis. If you experience severe, persistent pain in your stomach area (abdomen), with or without nausea or vomiting, you should stop using Wegovy and call your healthcare provider right away. This pain can sometimes spread from your abdomen to your back. Additionally, Wegovy may cause gallbladder problems, including gallstones. Symptoms like pain in your upper stomach, fever, yellowing of the skin or eyes (jaundice), or clay-colored stools warrant immediate medical attention, as some gallstones may require surgery [https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html]. Understanding these potential severe adverse events is key to safe medication use.

Why is Prior Authorization a Challenge for GLP-1s?

Prior authorization (PA) is a common hurdle for patients trying to access GLP-1 medications, adding a layer of complexity to the treatment process. This administrative requirement means that healthcare providers must obtain approval from an insurance company before a patient can receive certain medications or services. For GLP-1s, this often translates into delays and additional paperwork, making access to these effective drugs more difficult than it needs to be. The process is designed to ensure medical necessity and cost-effectiveness for the insurer, but it can create significant barriers for patients and prescribers alike. For more details, see Ozempic Savings Card Information.

The Nature of Prior Authorization

Prior authorization is a utilization management tool used by insurance companies to control costs and ensure that prescribed treatments meet specific criteria. For GLP-1 medications, especially those used for weight loss, insurers often require documentation proving that a patient meets certain clinical guidelines, has tried and failed other treatments, or has co-existing conditions that justify the prescription. This requirement is a significant challenge because it places an administrative burden on healthcare providers, who must dedicate time and resources to completing and submitting the necessary paperwork and clinical notes. The complexity of these requirements can vary widely between different insurance plans, adding to the frustration [https://www.pharmacytimes.com/view/navigating-glp-1-medications-prior-authorization-challenges-and-solutions].

Impact on Patient Access and Timeliness

The prior authorization process can lead to significant delays in patients starting their GLP-1 treatment. After a doctor prescribes the medication, the PA request must be submitted, reviewed by the insurance company, and then approved. This entire process can take days or even weeks, during which time a patient's condition may worsen or their motivation to start treatment might wane. These delays can be particularly detrimental for patients with urgent medical needs or those who are already struggling with the emotional and physical aspects of their health condition. The administrative burden effectively becomes a barrier to timely care.

Burden on Healthcare Providers

Healthcare providers and their staff bear a substantial burden when dealing with prior authorizations for GLP-1s. They must navigate complex insurance portals, gather extensive patient medical records, and often engage in back-and-forth communication with insurance reviewers. This takes valuable time away from direct patient care, potentially increasing staff workload and leading to burnout. The editorial team at CoverMyMeds recognizes this challenge, noting the need to simplify GLP-1 prior authorization [https://www.covermymeds.health/articles/provider-insights/simplify-glp-1-prior-authorization-with-covermymeds]. Streamlining this process is crucial for improving efficiency in healthcare settings.

Solutions to Simplify Prior Authorization

To address the challenges of prior authorization, various solutions are being developed and implemented. One such solution is the use of electronic prior authorization (ePA) platforms. Tools like CoverMyMeds aim to simplify the GLP-1 prior authorization process by digitizing and automating much of the submission and review. These platforms can help providers submit requests more efficiently, track their status, and receive faster responses from insurers. By reducing manual processes and improving communication, ePA can significantly decrease the time and effort required for obtaining approval, ultimately benefiting both providers and patients.

Navigating Specific Insurance Requirements

Navigating GLP-1 medications requires a clear understanding of specific prior authorization challenges and solutions. Each insurance provider will have its own set of criteria and procedures for approving GLP-1s. It is important for patients and providers to be familiar with these requirements to increase the likelihood of approval. This might involve documenting previous weight-loss attempts, providing detailed medical history, or demonstrating the presence of specific comorbidities. Proactive preparation of this documentation can help expedite the PA process. The article "Navigating GLP-1 Medications: Prior Authorization Challenges and Solutions" from Pharmacy Times highlights the ongoing need to manage these complexities effectively [https://www.pharmacytimes.com/view/navigating-glp-1-medications-prior-authorization-challenges-and-solutions].

The Role of Advocacy

Patient advocacy also plays a role in addressing prior authorization challenges. As more patients seek GLP-1 treatments, there is growing awareness and pressure on insurance companies to review and potentially revise their PA policies. Advocacy groups and healthcare organizations continue to push for more transparent, less burdensome prior authorization processes that prioritize patient access to medically necessary treatments. By understanding the system and advocating for improvements, patients and providers can collectively work towards a more equitable and efficient system for accessing GLP-1 medications.

Frequently Asked Questions

What is the average monthly cost of Wegovy without insurance?

The average monthly cost of Wegovy without insurance can vary depending on the form of the medication. For the weekly injection pen, cash-pay prices in 2026 typically range from about $199–$349 per month. If you opt for the new Wegovy pill, approved in late 2025, the cost without insurance is generally lower, ranging from $149–$299 per month through Novo Nordisk’s NovoCare Pharmacy. These prices are significantly lower than the medication's list price of $1,350 per month.

Does my insurance plan typically cover GLP-1 medications for weight loss?

Insurance coverage for GLP-1 medications used for weight loss is evolving, but it is not universally guaranteed. While some plans are starting to cover these medications, many still do not, or they have strict criteria. If your plan does cover Wegovy, you can expect an estimated monthly cost of $25–$150. It is essential to contact your specific insurance provider to understand your plan's coverage, deductibles, co-pays, and any prior authorization requirements for weight-loss medications.

Are there any patient assistance programs for Wegovy or Ozempic?

Yes, manufacturer savings programs are available for both Wegovy and Ozempic. For commercially covered Ozempic patients, a savings card can reduce the monthly cost to as little as $25 for up to a 3-month prescription. New uninsured and self-pay Ozempic patients can also pay $25 per month for the first 2 months of certain doses. Wegovy also has a specific savings program that patients can investigate to help reduce their out-of-pocket expenses.

What is the difference in cost between the Wegovy injection and the Wegovy pill?

For patients paying without insurance, the Wegovy pill is generally more affordable than the injection. The Wegovy injection pen typically costs $199–$349 per month for cash-pay patients in 2026. In contrast, the new Wegovy pill, when purchased without insurance through Novo Nordisk’s NovoCare Pharmacy, typically costs $149–$299 per month. This difference offers patients a choice based on both administration preference and budget.

What serious side effects should I be aware of when taking Wegovy?

Wegovy can cause serious side effects, including the possibility of thyroid tumors, including cancer. Patients should watch for symptoms like a lump in the neck, hoarseness, trouble swallowing, or shortness of breath. Other serious risks include inflammation of the pancreas (pancreatitis) and gallbladder problems like gallstones. It is crucial to inform your healthcare provider about your full medical history and any new symptoms you experience while on Wegovy.